Head-To-Head Review: Treace Medical Concepts (NASDAQ:TMCI) versus Microbot Medical (NASDAQ:MBOT)

Microbot Medical (NASDAQ:MBOT) and Treace Medical Concepts (NASDAQ:TMCI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends.

Insider & Institutional Ownership

16.3% of Microbot Medical shares are held by institutional investors. Comparatively, 84.1% of Treace Medical Concepts shares are held by institutional investors. 10.6% of Microbot Medical shares are held by company insiders. Comparatively, 24.4% of Treace Medical Concepts shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Microbot Medical and Treace Medical Concepts”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Microbot Medical	N/A	N/A	-$10.74 million	($0.89)	-0.99
Treace Medical Concepts	$198.53 million	1.70	-$49.53 million	($0.88)	-6.18

Microbot Medical has higher earnings, but lower revenue than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Microbot Medical, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Microbot Medical has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Comparatively, Treace Medical Concepts has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Microbot Medical and Treace Medical Concepts, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Microbot Medical	0	0	1	0	3.00
Treace Medical Concepts	0	6	0	0	2.00

Microbot Medical currently has a consensus price target of $7.00, indicating a potential upside of 694.55%. Treace Medical Concepts has a consensus price target of $7.30, indicating a potential upside of 34.19%. Given Microbot Medical’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Microbot Medical is more favorable than Treace Medical Concepts.

Profitability

This table compares Microbot Medical and Treace Medical Concepts’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Microbot Medical	N/A	-173.35%	-130.38%
Treace Medical Concepts	-32.08%	-49.53%	-26.50%

Summary

Microbot Medical beats Treace Medical Concepts on 7 of the 13 factors compared between the two stocks.

About Microbot Medical

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.

About Treace Medical Concepts

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.